Physician
Park Nicollet Clinic
Park Nicollet Clinic was paid $209.66M by Medicaid between Jan 2018 and Dec 2024, across 591 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 19% of everything it billed.
33Billing provider infoPARK NICOLLET CLINIC
ST LOUIS PARK, MN 55416
ST LOUIS PARK, MN 55416
33aNPI1780621904assigned 05/31/2006
33bProvider typeObstetrics & Gynecology Physician
28Total paid$209.66M
24GClaims6,015,921
24DCodes billed591
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in Minnesota
Rank by total paid#1 of 26
Median peer was paid$16K
This provider vs. median13,258×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LUHRS, JASON controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,022,112 | $9.66M | |
| 2019 | 1,017,395 | $37.90M | |
| 2020 | 901,502 | $34.94M | |
| 2021 | 1,138,703 | $47.32M | |
| 2022 | 870,690 | $35.60M | |
| 2023 | 596,708 | $24.43M | |
| 2024incomplete | 468,811 | $19.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 559,918 | 489,568 | $39.01M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 606,675 | 544,764 | $29.99M |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 4.0% | 155,998 | 153,678 | $8.36M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.7% | 62,679 | 56,661 | $5.63M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.1% | 72,064 | 68,868 | $4.51M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.1% | 45,848 | 43,717 | $4.33M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.9% | 59,521 | 57,383 | $4.00M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.7% | 65,240 | 39,628 | $3.62M |
| X5622 | 1.6% | 72,359 | 67,925 | $3.34M | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.5% | 54,510 | 51,418 | $3.05M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.4% | 44,702 | 42,686 | $2.91M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.4% | 37,798 | 36,999 | $2.90M |
579 more codes
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.4% | 59,295 | $2.84M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 102,729 | $2.75M |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 1.3% | 28,574 | $2.69M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.3% | 118,833 | $2.68M |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | 1.3% | 2,629 | $2.66M |
| 99223 | Prolong inpt eval add15 m | <1% | 22,665 | $2.00M |
| 99205 | Prolong outpt/office vis | <1% | 16,777 | $1.98M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 37,491 | $1.89M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 54,368 | $1.83M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 23,622 | $1.80M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 42,231 | $1.71M |
| 90837 | Psychotherapy session, about an hour | <1% | 17,953 | $1.60M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 22,312 | $1.56M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 44,045 | $1.56M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 17,573 | $1.49M |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 18,236 | $1.49M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 17,053 | $1.48M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,788 | $1.48M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 19,869 | $1.48M |
| 36415 | Collection of venous blood by venipuncture | <1% | 406,062 | $1.44M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 118,828 | $1.41M |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 36,359 | $1.15M |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 36,535 | $1.14M |
| 90691 | <1% | 10,987 | $1.09M | |
| 99310 | Prolong nursin fac eval 15m | <1% | 17,942 | $1.04M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 10,585 | $1.01M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 35,725 | $990K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 13,194 | $938K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 24,000 | $933K |
| 92015 | Determination of refractive state | <1% | 73,134 | $887K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 54,547 | $858K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 6,678 | $843K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 51,796 | $842K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 14,631 | $779K |
| 76801 | <1% | 10,375 | $757K | |
| 90717 | <1% | 5,905 | $727K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 21,857 | $721K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 10,692 | $711K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14,494 | $681K |
| 97161 | <1% | 11,950 | $681K | |
| 92551 | <1% | 102,703 | $677K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 13,870 | $672K |
| 76830 | Ultrasound, transvaginal | <1% | 9,807 | $631K |
| 99188 | <1% | 55,240 | $621K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 10,344 | $611K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 93,041 | $609K |
| 90750 | <1% | 4,892 | $607K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 5,130 | $604K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 30,706 | $601K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 805 | $593K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 10,646 | $567K |
| 97803 | <1% | 14,953 | $556K | |
| 99385 | <1% | 6,817 | $548K | |
| 90651 | <1% | 18,657 | $547K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 33,465 | $536K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 11,629 | $532K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 4,240 | $512K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 624 | $480K |
| 59410 | <1% | 975 | $469K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 7,183 | $465K |
| 96127 | <1% | 131,618 | $460K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 5,436 | $452K |
| 90686 | <1% | 86,909 | $440K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 6,376 | $439K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 7,846 | $437K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 74,250 | $436K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 41,276 | $435K |
| 80061 | Lipid panel | <1% | 39,419 | $430K |
| 99460 | <1% | 7,381 | $411K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 9,603 | $398K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 6,732 | $397K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 11,172 | $392K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 3,213 | $386K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 8,438 | $385K |
| 97162 | <1% | 7,048 | $369K | |
| 90715 | <1% | 22,659 | $369K | |
| 90732 | <1% | 4,340 | $362K | |
| 17110 | <1% | 5,828 | $343K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 13,112 | $343K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 38,801 | $324K |
| 93000 | <1% | 37,237 | $313K | |
| 59025 | Fetal non-stress test | <1% | 12,993 | $310K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,791 | $302K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,250 | $297K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,442 | $285K |
| 20610 | <1% | 8,209 | $267K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,151 | $260K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,578 | $260K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,729 | $259K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,072 | $258K |
| 76642 | <1% | 4,546 | $258K | |
| 99402 | <1% | 5,821 | $256K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 6,540 | $246K |
| 90734 | <1% | 18,342 | $240K | |
| 73562 | <1% | 10,705 | $232K | |
| 90677 | <1% | 3,138 | $230K | |
| 76825 | <1% | 1,323 | $226K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,850 | $225K |
| 73630 | <1% | 12,813 | $224K | |
| 97802 | <1% | 3,554 | $223K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 117 | $219K |
| 85027 | <1% | 40,621 | $219K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 4,115 | $215K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 26,634 | $213K |
| S0281 | Medical home program, comprehensive care coordination and planning, maintenance of plan | <1% | 12,473 | $211K |
| 99386 | <1% | 2,248 | $204K | |
| 99607 | <1% | 4,545 | $200K | |
| 0001A | <1% | 5,237 | $200K | |
| 80053 | Comprehensive metabolic panel | <1% | 20,522 | $193K |
| 81025 | <1% | 25,020 | $182K | |
| 91320 | <1% | 1,874 | $181K | |
| 99220 | <1% | 1,964 | $177K | |
| 99383 | <1% | 2,776 | $177K | |
| 59510 | <1% | 154 | $174K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 24,825 | $174K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,669 | $169K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,112 | $167K |
| 90746 | <1% | 3,220 | $167K | |
| 99384 | <1% | 2,275 | $164K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 10,686 | $164K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,678 | $161K |
| 0002A | <1% | 3,897 | $158K | |
| 99397 | <1% | 1,732 | $156K | |
| 93793 | <1% | 22,662 | $153K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 2,102 | $152K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,220 | $151K |
| 99401 | <1% | 5,950 | $146K | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 6,728 | $146K |
| 90961 | <1% | 1,399 | $143K | |
| 93971 | <1% | 3,696 | $141K | |
| 90632 | <1% | 2,997 | $139K | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 2,775 | $135K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,630 | $135K |
| 59426 | <1% | 390 | $133K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,904 | $132K |
| 99173 | <1% | 85,597 | $132K | |
| 92002 | <1% | 2,673 | $132K | |
| 92134 | <1% | 5,505 | $129K | |
| 99381 | <1% | 2,829 | $127K | |
| 0071A | <1% | 2,975 | $125K | |
| 81001 | <1% | 45,094 | $124K | |
| 58300 | <1% | 2,278 | $119K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 2,810 | $116K |
| 99605 | <1% | 2,251 | $116K | |
| 71045 | Radiologic examination, chest; single view | <1% | 23,677 | $114K |
| 82565 | <1% | 28,184 | $112K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,475 | $112K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,228 | $111K |
| 71250 | <1% | 1,767 | $111K | |
| 0004A | <1% | 3,284 | $109K | |
| 76818 | <1% | 1,357 | $108K | |
| 0072A | <1% | 2,539 | $108K | |
| 64615 | <1% | 1,236 | $107K | |
| 97165 | <1% | 1,769 | $106K | |
| 76821 | <1% | 1,688 | $104K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 570 | $99K |
| 73610 | <1% | 5,328 | $98K | |
| 99417 | Prolong home eval add 15m | <1% | 1,906 | $97K |
| 90670 | <1% | 36,893 | $94K | |
| 74018 | <1% | 6,697 | $93K | |
| 99462 | <1% | 4,039 | $93K | |
| 92523 | <1% | 746 | $92K | |
| 87210 | <1% | 17,605 | $91K | |
| 90480 | <1% | 3,584 | $90K | |
| 76536 | <1% | 1,340 | $87K | |
| 73110 | <1% | 4,193 | $87K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,433 | $85K |
| 99217 | <1% | 2,314 | $85K | |
| 88307 | <1% | 1,136 | $85K | |
| 88342 | <1% | 2,238 | $84K | |
| 73030 | <1% | 4,859 | $82K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 19,762 | $82K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,484 | $82K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,511 | $80K |
| 99221 | <1% | 1,604 | $79K | |
| 87480 | <1% | 4,342 | $77K | |
| 87660 | <1% | 4,338 | $77K | |
| 87510 | <1% | 4,322 | $77K | |
| 58301 | <1% | 1,347 | $77K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,250 | $73K |
| 92567 | <1% | 7,554 | $72K | |
| 0064A | <1% | 1,972 | $71K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 44 | $70K |
| 85018 | <1% | 32,472 | $70K | |
| 99606 | <1% | 2,195 | $68K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,792 | $68K |
| 80051 | <1% | 11,843 | $68K | |
| 84460 | <1% | 16,021 | $67K | |
| 95251 | <1% | 2,958 | $66K | |
| 73140 | <1% | 3,325 | $65K | |
| 94375 | <1% | 3,261 | $65K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 456 | $64K |
| 73221 | <1% | 503 | $64K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 3,726 | $63K |
| 76820 | <1% | 2,262 | $63K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 12,866 | $62K |
| 82947 | <1% | 19,217 | $62K | |
| 74183 | <1% | 339 | $62K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,010 | $61K |
| 99382 | <1% | 1,060 | $61K | |
| 90716 | <1% | 11,594 | $60K | |
| 73502 | <1% | 2,747 | $59K | |
| 0011A | <1% | 1,895 | $58K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,087 | $58K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 478 | $57K |
| 85610 | <1% | 18,461 | $57K | |
| 94729 | <1% | 1,847 | $57K | |
| 92083 | <1% | 1,550 | $57K | |
| 69210 | <1% | 2,601 | $56K | |
| 92557 | <1% | 2,503 | $56K | |
| 91322 | <1% | 495 | $55K | |
| 90713 | <1% | 5,002 | $55K | |
| 86780 | <1% | 4,514 | $55K | |
| 72100 | <1% | 2,811 | $54K | |
| 0054A | <1% | 1,402 | $54K | |
| G0008 | Administration of influenza virus vaccine | <1% | 8,188 | $54K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,708 | $54K |
| 93970 | <1% | 1,133 | $53K | |
| 0012A | <1% | 1,590 | $53K | |
| 0124A | <1% | 1,576 | $53K | |
| 64483 | <1% | 316 | $52K | |
| 83655 | <1% | 2,347 | $51K | |
| 74019 | <1% | 2,800 | $51K | |
| 70486 | <1% | 651 | $50K | |
| 84450 | <1% | 11,896 | $50K | |
| 90707 | <1% | 9,791 | $49K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 2,745 | $49K |
| 96130 | <1% | 456 | $49K | |
| 80076 | <1% | 7,367 | $48K | |
| 73130 | <1% | 2,668 | $48K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 4,662 | $47K |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 2,322 | $47K |
| 36416 | <1% | 15,791 | $46K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 663 | $45K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 2,520 | $45K |
| 59425 | <1% | 177 | $45K | |
| 77066 | Tomosynthesis, mammo | <1% | 443 | $44K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 734 | $44K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 457 | $43K |
| 54150 | <1% | 582 | $43K | |
| 81003 | <1% | 22,855 | $42K | |
| 96137 | <1% | 385 | $42K | |
| 82043 | <1% | 8,446 | $41K | |
| 82570 | <1% | 9,553 | $41K | |
| 93325 | <1% | 3,796 | $40K | |
| 0051A | <1% | 932 | $38K | |
| 86140 | <1% | 8,082 | $38K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,281 | $37K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 626 | $37K |
| 92060 | <1% | 865 | $37K | |
| 96161 | <1% | 27,611 | $37K | |
| 86803 | <1% | 2,727 | $36K | |
| 90674 | <1% | 7,639 | $36K | |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 1,609 | $36K |
| 52000 | <1% | 257 | $34K | |
| 82728 | <1% | 2,758 | $34K | |
| 90739 | <1% | 237 | $34K | |
| 96131 | <1% | 331 | $33K | |
| 99443 | <1% | 3,800 | $33K | |
| 90785 | <1% | 3,351 | $30K | |
| 92133 | <1% | 1,298 | $30K | |
| 31575 | <1% | 439 | $30K | |
| 90694 | <1% | 2,391 | $30K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,715 | $29K |
| 73600 | <1% | 1,681 | $29K | |
| 11981 | <1% | 390 | $29K | |
| 69209 | <1% | 3,179 | $29K | |
| 86481 | <1% | 292 | $29K | |
| 95012 | <1% | 2,640 | $28K | |
| 11900 | <1% | 1,012 | $28K | |
| 99201 | <1% | 1,229 | $28K | |
| 76770 | <1% | 494 | $28K | |
| 82248 | <1% | 5,842 | $28K | |
| 93248 | <1% | 1,584 | $26K | |
| 99442 | <1% | 3,980 | $26K | |
| 80050 | General health panel | <1% | 527 | $26K |
| 90636 | <1% | 342 | $26K | |
| 73560 | <1% | 1,836 | $25K | |
| 72156 | <1% | 135 | $25K | |
| 94060 | <1% | 935 | $24K | |
| 88304 | <1% | 2,222 | $24K | |
| 83690 | <1% | 3,762 | $24K | |
| 72141 | <1% | 197 | $23K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 309 | $23K |
| 87084 | <1% | 2,364 | $22K | |
| 92579 | <1% | 759 | $22K | |
| 90714 | <1% | 1,647 | $22K | |
| 85379 | <1% | 2,231 | $22K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 11,540 | $22K |
| 94726 | <1% | 699 | $21K | |
| 76827 | <1% | 455 | $21K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 539 | $21K |
| 84403 | <1% | 923 | $20K | |
| 84466 | <1% | 1,702 | $20K | |
| 90661 | <1% | 3,465 | $19K | |
| 72040 | <1% | 922 | $19K | |
| 90662 | <1% | 2,268 | $19K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 246 | $19K |
| 85652 | <1% | 8,118 | $19K | |
| 93016 | <1% | 1,446 | $18K | |
| 59515 | <1% | 42 | $18K | |
| 87340 | <1% | 1,917 | $18K | |
| 0052A | <1% | 425 | $18K | |
| 84702 | <1% | 1,245 | $17K | |
| 93296 | <1% | 1,147 | $17K | |
| 73080 | <1% | 992 | $16K | |
| 87088 | <1% | 2,260 | $16K | |
| 0031A | <1% | 420 | $16K | |
| 96136 | <1% | 398 | $16K | |
| 82607 | <1% | 1,158 | $16K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 101 | $15K |
| 70491 | <1% | 153 | $15K | |
| 82247 | <1% | 3,811 | $15K | |
| 96415 | <1% | 692 | $15K | |
| 0134A | <1% | 428 | $15K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 977 | $15K |
| 10060 | <1% | 247 | $15K | |
| 84439 | <1% | 1,856 | $15K | |
| 43235 | <1% | 202 | $14K | |
| 57454 | <1% | 213 | $14K | |
| 92552 | <1% | 750 | $14K | |
| 97116 | <1% | 638 | $14K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 365 | $14K |
| 29125 | <1% | 335 | $14K | |
| 77072 | <1% | 795 | $14K | |
| 81513 | <1% | 89 | $13K | |
| 0082A | <1% | 352 | $13K | |
| 83735 | <1% | 2,272 | $13K | |
| 87481 | <1% | 340 | $13K | |
| 96160 | <1% | 10,604 | $13K | |
| 95886 | <1% | 163 | $13K | |
| 70544 | <1% | 148 | $12K | |
| 87077 | <1% | 1,547 | $12K | |
| 93018 | <1% | 1,447 | $12K | |
| 82950 | <1% | 2,807 | $12K | |
| 87081 | <1% | 1,678 | $12K | |
| 84270 | <1% | 648 | $12K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 704 | $12K |
| 11102 | <1% | 150 | $11K | |
| 90653 | <1% | 144 | $11K | |
| 87070 | <1% | 1,503 | $11K | |
| 97166 | <1% | 226 | $11K | |
| V5266 | Battery for use in hearing device | <1% | 492 | $11K |
| 86762 | <1% | 850 | $11K | |
| 99306 | Prolong nursin fac eval 15m | <1% | 147 | $11K |
| 77002 | <1% | 166 | $11K | |
| 11104 | <1% | 118 | $11K | |
| 82310 | <1% | 2,597 | $11K | |
| 83540 | <1% | 1,783 | $10K | |
| 97035 | <1% | 1,285 | $10K | |
| 83516 | <1% | 864 | $10K | |
| 84703 | <1% | 1,483 | $10K | |
| 90473 | <1% | 870 | $10K | |
| 11982 | <1% | 133 | $10K | |
| 90474 | <1% | 1,224 | $10K | |
| 11750 | <1% | 99 | $10K | |
| 99464 | <1% | 271 | $10K | |
| 95117 | <1% | 1,730 | $10K | |
| 73590 | <1% | 627 | $10K | |
| 88312 | <1% | 352 | $9K | |
| 17000 | <1% | 239 | $9K | |
| 93976 | <1% | 89 | $9K | |
| 93320 | <1% | 649 | $9K | |
| 84132 | <1% | 2,282 | $9K | |
| 86850 | <1% | 1,022 | $9K | |
| 88341 | <1% | 157 | $9K | |
| 87186 | <1% | 1,088 | $8K | |
| 93350 | <1% | 193 | $8K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 416 | $8K |
| 86308 | <1% | 1,819 | $8K | |
| 84520 | <1% | 2,361 | $8K | |
| 71101 | <1% | 360 | $7K | |
| 0081A | <1% | 253 | $7K | |
| 88112 | <1% | 295 | $7K | |
| 73660 | <1% | 468 | $7K | |
| 93294 | <1% | 377 | $7K | |
| 72158 | <1% | 51 | $7K | |
| 83721 | <1% | 773 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 303 | $7K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 8,207 | $7K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 363 | $7K |
| 31231 | <1% | 56 | $7K | |
| 92556 | <1% | 378 | $7K | |
| 88141 | <1% | 187 | $7K | |
| 95806 | <1% | 147 | $6K | |
| 82465 | <1% | 1,731 | $6K | |
| 76870 | <1% | 87 | $6K | |
| 99218 | <1% | 114 | $6K | |
| 84146 | <1% | 354 | $6K | |
| 20550 | <1% | 216 | $6K | |
| 71271 | <1% | 51 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 80 | $6K |
| 86580 | <1% | 1,067 | $6K | |
| 82784 | <1% | 508 | $6K | |
| 20611 | <1% | 79 | $6K | |
| 0154A | <1% | 188 | $5K | |
| 99349 | <1% | 74 | $5K | |
| 84550 | <1% | 1,457 | $5K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 787 | $5K |
| 96101 | <1% | 88 | $5K | |
| 86706 | <1% | 518 | $5K | |
| 83001 | <1% | 280 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 380 | $5K |
| 97163 | <1% | 132 | $5K | |
| 90672 | <1% | 6,161 | $5K | |
| 82274 | <1% | 742 | $4K | |
| 82550 | <1% | 656 | $4K | |
| 85060 | <1% | 313 | $4K | |
| 87209 | <1% | 1,235 | $4K | |
| 99219 | <1% | 82 | $4K | |
| 98968 | <1% | 414 | $4K | |
| 82681 | <1% | 135 | $4K | |
| 99152 | <1% | 551 | $4K | |
| 99350 | Prolong home eval add 15m | <1% | 29 | $4K |
| 96112 | <1% | 45 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 67 | $4K |
| 0112A | <1% | 90 | $4K | |
| 99316 | <1% | 85 | $4K | |
| 11100 | <1% | 545 | $4K | |
| 99441 | <1% | 831 | $4K | |
| 92587 | <1% | 216 | $3K | |
| 51798 | <1% | 539 | $3K | |
| 87338 | <1% | 237 | $3K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 916 | $3K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 66 | $3K |
| 84100 | <1% | 742 | $3K | |
| 94618 | <1% | 147 | $3K | |
| 96040 | <1% | 89 | $3K | |
| 0074A | <1% | 159 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,367 | $3K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 72 | $3K |
| 99177 | <1% | 433 | $3K | |
| 97113 | <1% | 107 | $3K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 351 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,952 | $3K |
| 0083A | <1% | 66 | $3K | |
| 90620 | <1% | 74 | $3K | |
| 77085 | <1% | 82 | $3K | |
| 0298T | <1% | 151 | $2K | |
| 84075 | <1% | 685 | $2K | |
| 11301 | <1% | 34 | $2K | |
| 72197 | <1% | 12 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 226 | $2K |
| 99403 | <1% | 32 | $2K | |
| 84295 | <1% | 554 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,894 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 838 | $2K |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 14 | $2K |
| 76519 | <1% | 95 | $2K | |
| 86900 | <1% | 724 | $2K | |
| 86901 | <1% | 703 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 46 | $2K |
| 0034A | <1% | 102 | $2K | |
| 92285 | <1% | 114 | $2K | |
| 90710 | <1% | 6,993 | $2K | |
| 92591 | <1% | 30 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 58 | $2K |
| 70496 | <1% | 29 | $2K | |
| 99421 | <1% | 226 | $2K | |
| 93352 | <1% | 86 | $2K | |
| 99000 | <1% | 405 | $2K | |
| 98940 | <1% | 80 | $2K | |
| 0003A | <1% | 125 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 14 | $1K |
| 0111A | <1% | 33 | $1K | |
| 73090 | <1% | 89 | $1K | |
| 51702 | <1% | 41 | $1K | |
| 51701 | <1% | 49 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,066 | $1K |
| 0173A | <1% | 35 | $1K | |
| 70498 | <1% | 27 | $1K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 25 | $1K |
| 82670 | <1% | 69 | $1K | |
| 73552 | <1% | 72 | $1K | |
| 99451 | <1% | 51 | $1K | |
| 87147 | <1% | 370 | $1K | |
| 99226 | <1% | 20 | $1K | |
| 90962 | <1% | 14 | $1K | |
| 82962 | <1% | 976 | $1K | |
| 73700 | <1% | 15 | $1K | |
| 90723 | <1% | 29,443 | $1K | |
| 96417 | <1% | 23 | $1K | |
| 56820 | <1% | 13 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 73 | $980.90 |
| 85049 | <1% | 211 | $975.58 | |
| 96367 | <1% | 39 | $946.54 | |
| 87634 | <1% | 12 | $916.89 | |
| 11200 | <1% | 16 | $912.91 | |
| 90647 | <1% | 28,771 | $854.63 | |
| 46600 | <1% | 12 | $851.35 | |
| 58100 | <1% | 12 | $842.11 | |
| 96402 | <1% | 40 | $835.90 | |
| 11300 | <1% | 17 | $829.13 | |
| 90633 | <1% | 21,579 | $822.38 | |
| 93922 | <1% | 38 | $702.45 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 97 | $690.96 |
| 82951 | <1% | 50 | $667.65 | |
| 90680 | <1% | 22,927 | $664.90 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,137 | $661.31 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $660.01 |
| 77092 | <1% | 92 | $618.72 | |
| 96381 | <1% | 49 | $604.40 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 76 | $591.46 |
| 84156 | <1% | 151 | $581.60 | |
| 92593 | <1% | 15 | $577.77 | |
| 92235 | <1% | 12 | $576.80 | |
| 93244 | <1% | 43 | $575.68 | |
| 87205 | <1% | 173 | $575.53 | |
| 86480 | <1% | 31 | $575.09 | |
| 80069 | <1% | 73 | $572.05 | |
| 83970 | <1% | 12 | $520.86 | |
| 20600 | <1% | 14 | $509.38 | |
| 83520 | <1% | 32 | $502.67 | |
| 98967 | <1% | 65 | $484.32 | |
| 0092A | <1% | 14 | $443.61 | |
| 92553 | <1% | 16 | $432.61 | |
| 83718 | <1% | 63 | $430.44 | |
| 77080 | <1% | 12 | $428.54 | |
| 92136 | <1% | 12 | $422.74 | |
| 82746 | <1% | 51 | $412.52 | |
| 86003 | <1% | 13 | $373.96 | |
| 90696 | <1% | 8,639 | $365.78 | |
| 84402 | <1% | 12 | $329.39 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 42 | $305.30 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 179 | $291.72 |
| 86039 | <1% | 25 | $290.17 | |
| 97012 | <1% | 50 | $285.43 | |
| 96900 | <1% | 17 | $275.18 | |
| 72070 | <1% | 13 | $253.65 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 52 | $253.07 |
| 82374 | <1% | 52 | $243.17 | |
| 83002 | <1% | 12 | $242.16 | |
| 92555 | <1% | 14 | $239.88 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 388 | $239.24 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,214 | $234.82 |
| 82435 | <1% | 53 | $228.91 | |
| 86618 | <1% | 13 | $223.53 | |
| 84481 | <1% | 53 | $220.80 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 140 | $218.68 |
| 72220 | <1% | 12 | $213.02 | |
| 93295 | <1% | 14 | $196.32 | |
| 92550 | <1% | 13 | $158.35 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 16 | $139.62 |
| 97010 | <1% | 64 | $127.59 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 506 | $127.56 |
| 87220 | <1% | 26 | $118.83 | |
| 90744 | <1% | 836 | $105.80 | |
| 90700 | <1% | 8,157 | $90.66 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 258 | $78.94 |
| 86431 | <1% | 12 | $78.72 | |
| 91318 | <1% | 158 | $74.44 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 193 | $66.81 |
| 82040 | <1% | 12 | $62.03 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,277 | $61.02 |
| 81015 | <1% | 178 | $51.86 | |
| 94010 | <1% | 37 | $49.27 | |
| 90660 | <1% | 146 | $43.34 | |
| 86038 | <1% | 14 | $15.53 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 17 | $10.48 |
| 99336 | <1% | 31 | $8.42 | |
| 91305 | 0% | 134 | $0.00 | |
| 91319 | 0% | 346 | $0.00 | |
| 80047 | 0% | 201 | $0.00 | |
| 91301 | 0% | 130 | $0.00 | |
| 91307 | 0% | 332 | $0.00 | |
| 91303 | 0% | 13 | $0.00 | |
| 91306 | 0% | 66 | $0.00 | |
| 82150 | 0% | 18 | $0.00 | |
| 90381 | 0% | 14 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 16,255 | $0.00 |
| 81002 | 0% | 70 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 318 | $0.00 |
| 90685 | 0% | 1,343 | $0.00 | |
| 91300 | 0% | 693 | $0.00 | |
| 99404 | 0% | 16 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 271 | $0.00 |
| 91312 | 0% | 18 | $0.00 | |
| 76942 | 0% | 14 | $0.00 | |
| 90611 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLUHRS, JASON (VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Park Nicollet Methodist Hospital | St Louis Park, MN | $17.13M |
| Tria Orthopaedic Center LLC | Bloomington, MN | $7.30M |
| Park Nicollet Methodist Hospital | St Louis Park, MN | $990K |
| Tria Orthopaedic Center LLC | Bloomington, MN | $675K |
| Park Nicollet Methodist Hospital | St Louis Park, MN | $391K |
| Park Nicollet Methodist Hospital | St Louis Park, MN | $155K |
| Amery Regional Medical Center, INC | Amery, WI | $144K |
| Park Nicollet Methodist Hospital | St Louis Park, MN | $74K |
| Park Nicollet Methodist Hospital | St Louis Park, MN | $39K |
| Westfields Hospital, INC. | New Richmond, WI | $28K |
| Park Nicollet Methodist Hospital | St Louis Park, MN | $3K |
| Tria Orthopaedic Center LLC | Minneapolis, MN | $2K |
| Park Nicollet Methodist Hospital | Maple Grove, MN | $31.35 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.